Home | News | Find a Doctor | Ask a Question | Free

Histogen mentions Dr. Washenik


#1

Histogen added the following update re: the AAD conference to their site recently:

Histogen Hair Regrowth Clinical Trial Results to be Presented at AAD Annual Meeting
SAN FRANCISCO, March 7, 2009 - Attendees of the American Academy of Dermatology Annual Meeting, taking place March 6-10, 2009 in San Francisco, will receive a peek of Histogen’s preliminary hair regrowth clinical trial results in two presentations during the event. Data will be shared within an electronic poster from Histogen throughout the event, as well as within a podium presentation being given by Dr. Kenneth Washenik on advances in the treatment of hair loss on Sunday, March 8th.

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts grown under embryonic conditions, has recently released data from the 12 week timepoint of the Company’s first human clinical evaluation of ReGenicaTM for hair regrowth. This clinical trial is the first time that a single application of a treatment has shown an increase in new follicles, thickness of existing hairs, and number of hairs in pre-existing follicles, in a human study.

ReGenica, a proprietary liquid containing naturally secreted embryonic proteins and growth factors, is the first naturally stabilized and bioactive formulation of Wnt proteins and natural cofactors, which have been implicated in the formation of new hair follicles.

“It is definitely exciting to see the laboratory promise of Wnt’s effect on hair growth successfully translated into a clinical study,” said Dr. Washenik, who is the Medical Director of Bosley, the nation’s largest hair restoration group, and a faculty member in the Department of Dermatology at NYU’s School of Medicine.

Histogen scientists reported on the upregulation of several Wnt genes in response to the embryonic conditions in the Company’s proprietary bioreactors. In addition, the data has confirmed the activity of these Wnt proteins, through the nuclear translocation of beta catenin in human keratinocytes, the downstream signaling of Wnt-responsive TCF/ Lef promoter, and the presence of secreted Wnt 7a through western blot analysis.

Histogen began its outside-U.S. clinical trial of ReGenica for hair regrowth in November, with the goal of more rapidly obtaining human safety data which will allow the Company to progress with product development. Dr. Craig Ziering, the principal investigator on the trial, is a leading hair transplant specialist and the founder of Ziering Medical.

“For the millions of men and women who grapple every day with their hair loss, the results of our early testing indicate the potential for a phenomenal treatment option, particularly for women and men presenting with diffuse hair loss who are not good candidates for hair transplant surgery,” said Dr. Ziering. “In addition to growing new hair, it increases the diameter of existing hair, creating more volume and coverage, which are the primary goals of those seeking help for their thinning or balding hair.”

The trial is currently in progress, with the final scheduled 5 month timepoint upcoming. The Company expects to release full results from this first clinical trial in the first half of 2009.

Histogens’ electronic poster presentation, entitled Tissue-engineered human embryonic-like conditioned media for therapeutic applications, will be available for viewing throughout the American Academy of Dermatology Annual Meeting.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen’s proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen’s human Extracellular Matrix (ECM) and ReGenica, Histogen’s proprietary liquid formula.

http://www.histogeninc.com/aboutus/news_events.htm#21


#2

» Histogen added the following update re: the AAD conference to their site
» recently:
»
» Histogen Hair Regrowth Clinical Trial Results to be Presented at AAD
» Annual Meeting
» SAN FRANCISCO, March 7, 2009 - Attendees of the American Academy of
» Dermatology Annual Meeting, taking place March 6-10, 2009 in San Francisco,
» will receive a peek of Histogen’s preliminary hair regrowth clinical trial
» results in two presentations during the event. Data will be shared within
» an electronic poster from Histogen throughout the event, as well as within
» a podium presentation being given by Dr. Kenneth Washenik on advances in
» the treatment of hair loss on Sunday, March 8th.
»
» Histogen, Inc., a regenerative medicine company developing solutions based
» on the products of newborn fibroblasts grown under embryonic conditions,
» has recently released data from the 12 week timepoint of the Company’s
» first human clinical evaluation of ReGenicaTM for hair regrowth. This
» clinical trial is the first time that a single application of a treatment
» has shown an increase in new follicles, thickness of existing hairs, and
» number of hairs in pre-existing follicles, in a human study.
»
» ReGenica, a proprietary liquid containing naturally secreted embryonic
» proteins and growth factors, is the first naturally stabilized and
» bioactive formulation of Wnt proteins and natural cofactors, which have
» been implicated in the formation of new hair follicles.
»
» “It is definitely exciting to see the laboratory promise of Wnt’s effect
» on hair growth successfully translated into a clinical study,” said Dr.
» Washenik, who is the Medical Director of Bosley, the nation’s largest hair
» restoration group, and a faculty member in the Department of Dermatology at
» NYU’s School of Medicine.
»
» Histogen scientists reported on the upregulation of several Wnt genes in
» response to the embryonic conditions in the Company’s proprietary
» bioreactors. In addition, the data has confirmed the activity of these Wnt
» proteins, through the nuclear translocation of beta catenin in human
» keratinocytes, the downstream signaling of Wnt-responsive TCF/ Lef
» promoter, and the presence of secreted Wnt 7a through western blot
» analysis.
»
» Histogen began its outside-U.S. clinical trial of ReGenica for hair
» regrowth in November, with the goal of more rapidly obtaining human safety
» data which will allow the Company to progress with product development. Dr.
» Craig Ziering, the principal investigator on the trial, is a leading hair
» transplant specialist and the founder of Ziering Medical.
»
» “For the millions of men and women who grapple every day with their hair
» loss, the results of our early testing indicate the potential for a
» phenomenal treatment option, particularly for women and men presenting with
» diffuse hair loss who are not good candidates for hair transplant surgery,”
» said Dr. Ziering. “In addition to growing new hair, it increases the
» diameter of existing hair, creating more volume and coverage, which are the
» primary goals of those seeking help for their thinning or balding hair.”
»
» The trial is currently in progress, with the final scheduled 5 month
» timepoint upcoming. The Company expects to release full results from this
» first clinical trial in the first half of 2009.
»
» Histogens’ electronic poster presentation, entitled Tissue-engineered
» human embryonic-like conditioned media for therapeutic applications, will
» be available for viewing throughout the American Academy of Dermatology
» Annual Meeting.
»
» About Histogen
» Histogen, launched in 2007, seeks to redefine regenerative medicine by
» developing a series of high value products that do not contain embryonic
» stem cells or animal components. Through Histogen’s proprietary bioreactors
» that mimic the embryonic environment, newborn fibroblasts are encouraged to
» naturally produce the vital proteins and growth factors from which the
» Company has developed its rich product portfolio. Histogen has two product
» families - ExceltrixTM, Histogen’s human Extracellular Matrix (ECM) and
» ReGenica, Histogen’s proprietary liquid formula.
»
»
» http://www.histogeninc.com/aboutus/news_events.htm#21

seems very promising… it says about the born of new hairs follicles for the first time… if the PHASE 1 is already so promising maybe the phase 2 will be shortest… maybe without a phase 3…


#3

» seems very promising… it says about the born of new hairs follicles for
» the first time… if the PHASE 1 is already so promising maybe the phase 2
» will be shortest… maybe without a phase 3…

ReGenica basically has Wnt proteins in it - the same stuff Dr. Cotsarelis’ 2007 research study was about. Time will tell if this treatment will be good enough to give us decent hair.


#4

as he knows the subject.

» “It is definitely exciting to see the laboratory promise of Wnt’s effect
» on hair growth successfully translated into a clinical study,” said Dr.
» Washenik, who is the Medical Director of Bosley, the nation’s largest hair
» restoration group, and a faculty member in the Department of Dermatology at
» NYU’s School of Medicine.


#5

how much we have to wait before to know if it works or not? there is a released data of the next upgrade? or something like that?

and about follica? why nothing is coming out since months and months? :stuck_out_tongue:


#6

» as he knows the subject.
»
» » “It is definitely exciting to see the laboratory promise of Wnt’s
» effect
» » on hair growth successfully translated into a clinical study,” said Dr.
» » Washenik, who is the Medical Director of Bosley, the nation’s largest
» hair
» » restoration group, and a faculty member in the Department of Dermatology
» at
» » NYU’s School of Medicine.

Don’t forget he was the one who said hair multiplication will be available in 5 years, that was about 5 years ago when he said that.

Let’s also not forget he works for Bosley.


#7

I guess I was curious as to whether anyone knew his role within Histogen. The press release states,

“Data will be shared within an electronic poster from Histogen throughout the event, as well as within a podium presentation being given by Dr. Kenneth Washenik on advances in the treatment of hair loss on Sunday, March 8th.”

He’s giving a “podium presentation” for them so…that would imply he’s involved.


#8

» as he knows the subject.

some twisted logic of this board, if Dr. Washenik is mentioned in the same context as bosley hair transplant, then he is a butcher, but if he is mentioned in the context of hair multiplication, then his words are very significant,


#9

» » as he knows the subject.
»
»
» some twisted logic of this board, if Dr. Washenik is mentioned in the same
» context as bosley hair transplant, then he is a butcher, but if he is
» mentioned in the context of hair multiplication, then his words are very
» significant,

Aderans own Bosleys,Wig manufactures,etc = they have the funds to go further!

Correct me if I’m wrong


#10

» » » as he knows the subject.
» »
» »
» » some twisted logic of this board, if Dr. Washenik is mentioned in the
» same
» » context as bosley hair transplant, then he is a butcher, but if he is
» » mentioned in the context of hair multiplication, then his words are
» very
» » significant,
»
» Aderans own Bosleys,Wig manufactures,etc = they have the funds to go
» further!
»
» Correct me if I’m wrong

You are 100% correct. Aderans/Bosley have deep pockets, they get almost unlimited funding from their wigs and hair transplant sales, they are the world’s #1 wigs seller and I think they are easily top 3 in the world for hair transplant sales. With that kind of cash as cushion, it’s almost impossible for Aderans to fail, they can afford to keep trying indefinitely until they get it right! Intercytex doesn’t have that luxury, it is more of a pure biotech research firm than anything else, investors will withdraw if they don’t see their returns on investment after a couple of years.


#11

» … With that kind of cash as cushion, it’s almost
» impossible for Aderans to fail, they can afford to keep trying indefinitely
» until they get it right! …

this is one of the most entertaining boards all over the net


#12

» » … With that kind of cash as cushion, it’s almost
» » impossible for Aderans to fail, they can afford to keep trying
» indefinitely
» » until they get it right! …
»
» this is one of the most entertaining boards all over the net

To be sure.


#13

»
» You are 100% correct. Aderans/Bosley have deep pockets, they get almost
» unlimited funding from their wigs and hair transplant sales, they are the
» world’s #1 wigs seller and I think they are easily top 3 in the world for
» hair transplant sales. With that kind of cash as cushion, it’s almost
» impossible for Aderans to fail, they can afford to keep trying indefinitely
» until they get it right! Intercytex doesn’t have that luxury, it is more
» of a pure biotech research firm than anything else, investors will withdraw
» if they don’t see their returns on investment after a couple of years.

You may be right about that but the other thing to consider is whether it is in Aderans’ best interest to introduce a viable protocol for hair multiplication. As you correctly pointed out, they have pretty much conquered the hair loss business in the world already (both wigs and hair transplant), what’s the incentive for them to introduce a brand new treatment that may very likely obsolete both wigs and hair transplants?


#14

Because they know it is going to happen by somebody. And if that somebody is not them, they are out of business forever.


#15

» You may be right about that but the other thing to consider is whether it
» is in Aderans’ best interest to introduce a viable protocol for hair
» multiplication. As you correctly pointed out, they have pretty much
» conquered the hair loss business in the world already (both wigs and hair
» transplant), what’s the incentive for them to introduce a brand new
» treatment that may very likely obsolete both wigs and hair transplants?

It is absolutely in Aderans’ best interest to introduce HM because:

  1. The wig market is vastly larger than just wigs worn by people with hair loss.
  2. They’ll make a lot more money from HM than from HT because it is a far superior solution to hair transplants, which many balding people don’t get because of its great limitations and shortcomings.
  3. If they won’t come out with HM first, then someone else might.

Believe me, if they didn’t think it was in their best interest, they wouldn’t be sinking millions into ARI.


#16

» » You may be right about that but the other thing to consider is whether
» it
» » is in Aderans’ best interest to introduce a viable protocol for hair
» » multiplication. As you correctly pointed out, they have pretty much
» » conquered the hair loss business in the world already (both wigs and
» hair
» » transplant), what’s the incentive for them to introduce a brand new
» » treatment that may very likely obsolete both wigs and hair transplants?

Simple - there’s more money in HM than HTs or whigs.

  1. The number of people willing to get a whig is limited. Most know they look silly and very few are willing to put up with them. Further, they could charge $50,000 for HM and still get more people to sign up for it than would get one of their cheaper whig systems.

  2. HM will make HTs obsolete, but they will be able to charge more for less work. Further, they will expand their potential market; most are unwilling to go through an HT (I know I certainly wouldn’t), but many would be willing to have HM done. Further, if they are working on an HM protocol that grows hair outside the scalp and is then later implanted, HM becomes a supplement to HTs, not a replacement.

So you can see how this would in fact allow Aderans to make more, not less, money by expanding their market and volume (by pulling in people who wouldn’t wear a whig/get an HT), reducing their labor (and thus cost), and increasing their rates. If none of that were the case, they wouldn’t be spending money on the trails, nor fund the research to begin with.


#17

lol. so just another treatment that works only for ppl who actually still have their hair :slight_smile: YEAH GREAT :slight_smile:


#18

» lol. so just another treatment that works only for ppl who actually still
» have their hair :slight_smile: YEAH GREAT :slight_smile:

It says it will work particularly well for diffuse thinners because they are not good candidates for hair transplants, it doesn’t say anything about being for diffuse thinners only.


#19

» » lol. so just another treatment that works only for ppl who actually
» still
» » have their hair :slight_smile: YEAH GREAT :slight_smile:
»
» It says it will work particularly well for diffuse thinners because they
» are not good candidates for hair transplants, it doesn’t say anything about
» being for diffuse thinners only.

mmmh, I agree with debris. If it worked well for totally bald guys, then they would say something like this: “it will work particularly well for totally bald guys who are depleted of donor hair and are totally helpless”. But instead, they focused in “diffuse thinners”.
Also, we see in the published photos that they are testing it on difuse thinners.
Boomer.
As of today, Histogen doesn’t seem like the cure we are waiting for.

Lets remember that ICX also said that TRC would be perfect for people who starts thinning. They talked about periodically treat these persons to keep theit hair. This kind of talk is the talk of a procedure that does not work, oviously. If a procedure works well, they will treat totally bald scalps, because results are much more visible and easier to study.
When they use “difuse thinning” trialists, its because something is not going well…


#20

» mmmh, I agree with debris. If it worked well for totally bald guys, then
» they would say something like this: “it will work particularly well for
» totally bald guys who are depleted of donor hair and are totally helpless”.
» But instead, they focused in “diffuse thinners”.
» Also, we see in the published photos that they are testing it on difuse
» thinners. Boomer. As of today, doesn’t seem like the cure we are waiting
» for.

Well, as a diffuse thinner, I’m actually happy about this, but I’m curious about why something would work for one thinning pattern and not another. They are thinning for the same (if not agreed-upon) reasons, so why would a treatment work for one “type” of balding and not another? Are their in fact differences in the cause of these two patterns? Diffuse loss seems to be more rare.